Merck Receives FDA Approval to Update Label for Winrevair
Merck & Co. announced that it has received U.S. Food and Drug Administration (FDA) approval to update the label of its drug, Winrevair, which is co-marketed with Bristol Myers Squibb. The updated labeling recognizes the benefits of using Winrevair earlier in a patient's treatment course for pulmonary arterial hypertension. This change reflects new clinical evidence supporting early intervention and could influence prescribing practices among healthcare providers. Winrevair is part of Merck’s portfolio targeting cardiovascular diseases, specifically addressing conditions where timely therapeutic action can significantly impact outcomes.
Topics: drug approvals pharmaceuticals pulmonary arterial hypertension